BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks

Reuters

Jan 10, 2025

** Biotech firm Climb Bio's CLYM.O shares rise ~16% to $2.17

** CLYM announces license deal with Beijing Mabworks Biotech Co Ltd in a filing

** CLYM buys exclusive right to develop, manufacture, and commercialize Mabworks' MIL116 antibody outside of China, Hong Kong, Macau, and Taiwan, with non-exclusive rights for global clinical studies in those regions

** MIL116, now called CLYM116, is an antibody developed by Mabworks for treating autoimmune diseases, including IgA nephropathy and B-cell mediated diseases

** Autoimmune diseases occur when the immune system attacks the body's own tissues

** CLYM will pay Mabworks $9 mln upfront and up to $832 mln upon reaching certain commercial milestones

** Mabworks has the first right to develop and sell the antibody in China - filing

** CLYM fell 35.7% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502860910"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502860910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502860910?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502860910","market":"us","top_or_hot":-1,"title":"BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks</title></head><body>** Biotech firm Climb Bio's CLYM.O shares rise ~16% to $2.17** CLYM announces license deal with Beijing Mabworks Biotech Co Ltd in a filing** CLYM buys exclusive right to develop, manufacture, and commercialize Mabworks' MIL116 antibody outside of China, Hong Kong, Macau, and Taiwan, with non-exclusive rights for global clinical studies in those regions** MIL116, now called CLYM116, is an antibody developed by Mabworks for treating autoimmune diseases, including IgA nephropathy and B-cell mediated diseases** Autoimmune diseases occur when the immune system attacks the body's own tissues** CLYM will pay Mabworks $9 mln upfront and up to $832 mln upon reaching certain commercial milestones** Mabworks has the first right to develop and sell the antibody in China - filing** CLYM fell 35.7% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2025-01-10 23:08\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks</title></head><body>** Biotech firm Climb Bio's CLYM.O shares rise ~16% to $2.17** CLYM announces license deal with Beijing Mabworks Biotech Co Ltd in a filing** CLYM buys exclusive right to develop, manufacture, and commercialize Mabworks' MIL116 antibody outside of China, Hong Kong, Macau, and Taiwan, with non-exclusive rights for global clinical studies in those regions** MIL116, now called CLYM116, is an antibody developed by Mabworks for treating autoimmune diseases, including IgA nephropathy and B-cell mediated diseases** Autoimmune diseases occur when the immune system attacks the body's own tissues** CLYM will pay Mabworks $9 mln upfront and up to $832 mln upon reaching certain commercial milestones** Mabworks has the first right to develop and sell the antibody in China - filing** CLYM fell 35.7% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nL4N3O610J:1","article_id":"2502860910","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502860910","pubTimestamp":1736521733,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks** Biotech firm Climb Bio's CLYM.O shares rise ~16% to $2.17** CLYM announces license deal with Beijing Mabworks Biotech Co Ltd in a filing** CLYM buys exclusive right to develop, manufacture, and commercialize Mabworks' MIL116 antibody outside of China, Hong Kong, Macau, and Taiwan, with non-exclusive rights for global clinical studies in those regions** MIL116, now called CLYM116, is an antibody developed by Mabworks for treating autoimmune diseases, including IgA nephropathy and B-cell mediated diseases** Autoimmune diseases occur when the immune system attacks the body's own tissues** CLYM will pay Mabworks $9 mln upfront and up to $832 mln upon reaching certain commercial milestones** Mabworks has the first right to develop and sell the antibody in China - filing** CLYM fell 35.7% in 2024 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLYM":"CLIMB BIO INC"},"translate_title":"BUZZ-Climb Bio因与北京Mabworks达成抗体许可协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9},"content_text":"BUZZ-Climb Bio rises on antibody license deal with Beijing Mabworks** Biotech firm Climb Bio's CLYM.O shares rise ~16% to $2.17** CLYM announces license deal with Beijing Mabworks Biotech Co Ltd in a filing** CLYM buys exclusive right to develop, manufacture, and commercialize Mabworks' MIL116 antibody outside of China, Hong Kong, Macau, and Taiwan, with non-exclusive rights for global clinical studies in those regions** MIL116, now called CLYM116, is an antibody developed by Mabworks for treating autoimmune diseases, including IgA nephropathy and B-cell mediated diseases** Autoimmune diseases occur when the immune system attacks the body's own tissues** CLYM will pay Mabworks $9 mln upfront and up to $832 mln upon reaching certain commercial milestones** Mabworks has the first right to develop and sell the antibody in China - filing** CLYM fell 35.7% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}